Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Johns Hopkins University Baltimore-India Clinical Trials Unit